Gaucher disease
EMA and FDA harmonise over development of Gaucher drugs
July 5, 2017Medical Communications, Research and Development, Sales and Marketing EMA, FDA, Gaucher disease
The EMA and the FDA have announced that they have developed a joint proposal to promote more efficient means of …
NICE U-turns to recommend Sanofi Gaucher disease drug
June 2, 2017Medical Communications, Sales and Marketing Gaucher disease, NICE, Sanofi
It has been revealed that NICE has reached the decision to recommend Sanofi’s Cerdelga (eligustat) for use on the NHS …
FDA approves Sanofi’s new rare disease drug
August 20, 2014Research and Development, Sales and Marketing Elelyso, Gaucher disease, Genzyme, Sanofi, eliglustat
Sanofi’s biologics unit Genzyme has been granted approval for a new drug to treat the rare genetic disorder Gaucher’s disease. …
Pfizer submits Gaucher drug to EMA
November 29, 2010Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa
Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
